Developing treatment of immune-mediated & autoimmune diseases.

VIS171 is a modified interleukin-2 (IL-2) molecule (mIL-2) designed to specifically activate and amplify regulatory T lymphocyte (Treg) populations. The safety of VIS171 is currently being evaluated in a phase 1 trial.